Imbria Pharmaceuticals
Imbria Pharmaceuticals is a Boston-based, clinical-stage biopharmaceutical company developing ninerafaxstat, a first-in-class partial fatty acid oxidation inhibitor that improves cardiac energetics, for patients with non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction.
- Company typePrivate
- Founded2021
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Imbria Pharmaceuticals does
Imbria Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, founded around 2018 and developing a single lead asset, ninerafaxstat, for serious cardiovascular diseases. The company targets patients with non-obstructive hypertrophic cardiomyopathy (nHCM, approximately 250,000-400,000 US patients) as its primary indication, with secondary development in heart failure with preserved ejection fraction (HFpEF, affecting over 6.7 million Americans) and stable angina. The therapeutic hypothesis is that cardiovascular disease is driven in part by impaired cardiac energetics, and that modulating myocardial substrate utilization could address an underlying disease mechanism not targeted by existing hemodynamic therapies.
Ninerafaxstat is a partial fatty acid oxidation (pFOX) inhibitor that shifts the heart's metabolic preference from fatty acids toward glucose, increasing mitochondrial ATP generation efficiency per unit of oxygen consumed. The drug is orally administered with no dose titration or monitoring required, has no clinically significant drug-drug interactions, and does not produce adverse hemodynamic effects (no impact on heart rate, blood pressure, or ejection fraction), making it combinable with standard-of-care cardiovascular therapies. Imbria has used hyperpolarized multi-nuclear MR spectroscopy to directly measure cardiac PCr/ATP ratios in the IMPROVE-DiCE Phase 2a trial, and Phase 2 data has shown statistically significant improvements in KCCQ-CSS (9.3 point LS mean difference), ventilatory efficiency (VE/VCO2 slope -2.1), 6-minute walk distance (~14m), and LV stroke volume augmentation (~188%). The current FORTITUDE-HCM Phase 2b trial is enrolling approximately 165 patients globally across US sites with planned UK and EU expansion, supported by a research partnership with the University of Oxford.
Imbria is pre-revenue with no approved products, no commercial sales, and no current pricing. The business model contemplates future pharmaceutical product sales upon regulatory approval, distributed through standard pharmacy and hospital channels with enterprise field sales targeting cardiologists and heart failure specialists. Operations are funded by venture capital, with a $57.5 million Series B led by Deep Track Capital in April 2025 extended in November 2025 with new investor AXA IM Alts, building on prior Series A rounds led by RA Capital Management and Sanofi Ventures. The company holds FDA Orphan Drug Designation for ninerafaxstat in symptomatic nHCM (June 2026) and operates a clinical-stage organization of approximately 1-10 disclosed senior leaders under CEO Alvin Shih and CMO Albert Kim.
Imbria Pharmaceuticals firmographics
Firmographics- Name
- Imbria Pharmaceuticals
- Legal name
- Imbria Pharmaceuticals, Inc.
- Website
- https://imbria.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Imbria Pharmaceuticals is a Boston-based, clinical-stage biopharmaceutical company developing ninerafaxstat, a first-in-class partial fatty acid oxidation inhibitor that improves cardiac energetics, for patients with non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction.
- Ownership category
- akta.pro rank
Imbria Pharmaceuticals industry classification
Industry- Product category
- Cardiovascular Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Mining & Quarrying Of Nonmetallic Minerals (No Fuels) (1400)
- akta.pro primary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
- akta.pro secondary industries
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Cardiac Rehabilitation & Secondary Prevention (HLAKABAJ)
Keywords
Where Imbria Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Imbria Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Ninerafaxstat commercialization: Imbria is a clinical-stage biopharmaceutical company with no current revenue. The company is developing ninerafaxstat for cardiovascular indications including non-obstructive hypertrophic cardiomyopathy (nHCM) and heart failure with preserved ejection fraction (HFpEF). Future revenue will come from pharmaceutical product sales upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Imbria Pharmaceuticals product offering
Product offeringCore offering
Imbria Pharmaceuticals is developing ninerafaxstat, a first-in-class partial fatty acid oxidation (pFOX) inhibitor that targets cardiac energy metabolism. The oral drug shifts cardiac substrate utilization from fatty acids to glucose, enhancing mitochondrial ATP production efficiency. It is being advanced through clinical trials for non-obstructive hypertrophic cardiomyopathy (nHCM), heart failure with preserved ejection fraction (HFpEF), and stable angina, addressing fundamental energy deficits in cardiovascular disease.
Product overview
Imbria Pharmaceuticals is a clinical-stage biotechnology company developing a single lead product candidate, ninerafaxstat, a novel partial fatty acid oxidation (pFOX) inhibitor. The drug is designed to improve cardiac energetics by shifting the heart's fuel preference from fatty acids to glucose, enhancing mitochondrial ATP production. Ninerafaxstat is being advanced through Phase 2b clinical trials (FORTITUDE-HCM) for non-obstructive hypertrophic cardiomyopathy (nHCM), with additional development planned for heart failure with preserved ejection fraction (HFpEF) and stable angina.
Differentiator
Problem solved
Functional benefit
Products and services
- Ninerafaxstat Ninerafaxstat is an oral, first-in-class partial fatty acid oxidation (pFOX) inhibitor designed as a cardiac mitotrope that shifts the heart's metabolic preference from fatty acids to glucose, producing more ATP per unit of oxygen consumed. The drug requires no dose titration or monitoring, has no clinically significant drug-drug interactions, and can be used on top of standard of care cardiovascular treatments. It is being developed for patients with non-obstructive hypertrophic cardiomyopathy (nHCM), heart failure with preserved ejection fraction (HFpEF), and stable angina. The FORTITUDE-HCM Phase 2b trial is currently enrolling approximately 165 patients globally.
Quantifiable outcome
- Statistically significant improvement in KCCQ-CSS score with 9.3 point LS mean difference (p=0.04) in patients with baseline KCCQ-CSS ≤80 in IMPROVE-HCM trial
- +4 more outcomes
Companies that use Imbria Pharmaceuticals
Customer profileSegments2 records
Ideal customer profiles2 records
Imbria Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Imbria Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Hypertrophic Cardiomyopathy Association (HCMA)corePartnership with HCMA to support recruitment for FORTITUDE-HCM Phase 2b clinical trial evaluating ninerafaxstat in non-obstructive hypertrophic cardiomyopathy. HCMA will support trial recruitment by educating the HCM community through outreach programs, conferences, patient communications, and surveys to help connect patients and clinicians with trial information and enrollment resources.
- University of OxfordcoreClinical trial partnership for IMPROVE-DiCE Phase 2a trial conducted at Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Radcliffe Department of Medicine at the University of Oxford, UK. Led by Professor Oliver Rider.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Imbria Pharmaceuticals competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Imbria Pharmaceuticals social profiles
Digital presenceImbria Pharmaceuticals compliance and trust
Trust signalCompliance1 record
Imbria Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Imbria Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles14 records
Imbria Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Imbria Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Imbria Pharmaceuticals
What does Imbria Pharmaceuticals do?
Imbria Pharmaceuticals is developing ninerafaxstat, a first-in-class partial fatty acid oxidation (pFOX) inhibitor that targets cardiac energy metabolism. The oral drug shifts cardiac substrate utilization from fatty acids to glucose, enhancing mitochondrial ATP production efficiency. It is being advanced through clinical trials for non-obstructive hypertrophic cardiomyopathy (nHCM), heart failure with preserved ejection fraction (HFpEF), and stable angina, addressing fundamental energy deficits in cardiovascular disease.
Is Imbria Pharmaceuticals a public or private company?
Imbria Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Imbria Pharmaceuticals founded?
Imbria Pharmaceuticals was founded in 2021. It employs 1 to 10 people.
Where is Imbria Pharmaceuticals based?
Imbria Pharmaceuticals is headquartered in Boston, United States, in the North America region.
How does Imbria Pharmaceuticals make money?
One revenue line is on record: ninerafaxstat commercialization.
Does Imbria Pharmaceuticals have an API?
No public API is recorded for Imbria Pharmaceuticals.
What industry is Imbria Pharmaceuticals in?
Imbria Pharmaceuticals's product category is Cardiovascular Pharmaceuticals. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 3254 and its SIC code is 1400.